Steep Hill Labs, a cannabis science and technology company has entered a joint venture with iCAN:Israel-Cannabis to leverage Steep Hill’s science, IP, methodology, global collaboration and brand.
The companies announced the venture at Israel’s premier medical cannabis conference, CannaTech.
The companies said that they plan to open an analytical, genetic, and R&D lab in Israel to further research the cannabis plant, stating that cannabis data analysis will take the medicinal cannabis industry to the next level.
Steep Hill Israel said that it plans to empower growers with the technology to breed specific strains, based on genetics and expected chemical profiles for specific patient conditions/diseases. Steep Hill’s collaborative research will provide the knowledge about the cannabis plant and its active compounds to be fully understood, and no longer demonized and misunderstood, the company said. Furthermore, DNA based testing; can be used not only for genetic analysis and strain identification, but also for safety and quality assurance.
Jmichaele Keller, CEO of Steep Hill Labs said that cannabis analysis is an enormous gateway to big data and machine learning algorithms which Steep Hill can turn into commercialized global products set at Israeli standards.